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Cardiac serum biomarker results will not be available for this 
cohort of patients. 
Cardiac MRI is performed on a Siemens 3.0 Tesla scanner. The 
imaging protocol includes short axis scans of the base, mid 
and apical positions of the left ventricle and 4-chamber scan, 
including standard cine scans for anatomy, mass and 
function.  
The cardiac MRI images are registered with the radiotherapy 
planning CT scan and analysed for the radiotherapy dose to 
cardiac macrostructures and the left ventricle 17 segment 
model. The radiotherapy dose will be correlated with cardiac 
MRI, ECG and cardiac biomarkers. 
Results: To date 24 patients have been recruited, 7 were 
withdrawn due to issues with completion of cardiac MRI scan, 
and 5 have completed the study.  
On treatment radiotherapy physics data has been analysed 
for 12 of these patients. Maximum radiotherapy dose was 
highest in the left (mean 4680cGy, 95CI (3711-5649) and right 
atria (mean 3885cGy, 95CI 2635-5135) compared to the left 
(mean 2625 cGy, 95CI 1567-3682) and right ventricles (mean 
2448 cGy, 95CI 1678-3217) (p=0.005 and p=0.021 
respectively).  
Furthermore review of the dose to the left ventricular 
segments, identified areas which received radiation dose in 
excess of 35Gy. 
Cardiac function, measured by cardiac MRI, was significantly 
affected during radiotherapy. There was a small but 
significant relative reduction in LVEF compared to baseline (-
4.7%, p=0.040). In comparison, right sided cardiac function 
was more impaired, with a mean relative fall in RVEF of 
21.6% (95CI 13.01-30.26, p < 0.0001). 
Conclusions: Preliminary evidence suggests an acute effect 
on right heart function by thoracic radiotherapy in NSCLC. 
Further analyses will be performed as the data matures. 
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Purpose/Objective: Patients with soft tissue sarcoma (STS) 
frequently develop pulmonary metastasis limiting their long-
term survival. Lung metastases have historically been treated 
with surgical resection and/ or chemotherapy. Few reports 
are available in the literature describing the value of 
stereotactic body radiation therapy (SBRT) as an alternative 
to surgical treatment . The aim of this study was to evaluate 
toxicity, rate of local control and survival in lung metastatic 
STS patients underwent SBRT. 
Materials and Methods: From February 2008 to May 2014, 28 
patients for 55 lung lesions were treated at our Institution. 
SBRT was performed in patients with good Performance 
Status (1-2 ECOG) and unsuitable for surgical resection, with 
controlled primary tumor and number of lung metastases ≤ 4. 
All patients were evaluated at multidisciplinary team 
including thoracic surgeon, medical oncologist and radiation 
oncologist. According to site and maximum diameter several 
radiation schedule were used: 30 Gy/1 fr, 60 Gy/3 fr, 60 
Gy/8 fr and 48 Gy /4 fr. The plan was generated using 
Volumetric Modulated Arc Therapy (VMAT). Clinical outcome 
was evaluated by thoracic and abdominal CT scan before 
SBRT and than every 3 months. Toxicity was evaluated with 
CTCAE scale version 4.0. 
Results: Leiomyosarcoma (36%), and synovial sarcoma (25%) 
were the most common histologies. Five patients (18%) 
initially presented with pulmonary metastasis, whereas 23 
(82%) developed them at a median time of 51 months (range 
11-311 months ) from the initial diagnosis. The median 
follow-up time from initial diagnosis was 65 months (range 5-
39 months) and from SBRT was 21 months (range 2-80 
months). No severe toxicity (grade III-IV) was recorded and 
no one patients required hospitalisation. The local control 
rate was 94% (54/55 lesions). At the last follow up 15/28 
patients (54%) were alive and 13/28 (46%) died. All patients 
died for distant progression. The 1, 2 and 3 years Overall 
Survival was 88%, 57% and 46%.respectively. 
Conclusions: SBRT provides excellent local control of 
pulmonary metastasis from STS and a promising influence on 
survival. SBRT should be considered for all patients with PM 
and evaluated in a multidisciplinary team. Further 
investigation is warranted to identify patients that could 
received benefit from local treatment  
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Purpose/Objective: Testing a model on external data 
indicates generalizability and is seen as a requirement before 
using a model in daily clinical practice. Although it is of 
utmost importance, reporting of model performance is 
generally limited to one number: the Area Under the Curve 
(AUC) for a dichotomous outcome or the C statistic for time-
to-event outcome. However, by focusing on one performance 
measure, important information is neglected. A more 
extensive approach could raise new research questions, 
indicate underlying causes and mechanisms, and highlight 
differences in diagnostic, treatment or follow-up procedures, 
between countries and hospitals. We used three external 
datasets to test a previously developed prediction model for 
survival of stage III NSCLC in an innovative way. 
 
 
 
 
 
 
3rd ESTRO Forum 2015                                                                                                                                         S327 
 
Materials and Methods:  
 
A previously developed survival model for stage III NSCLC, 
based on 548 patients, was tested on datasets from three 
different hospitals situated in the US (1), Belgium (2) and the 
Netherlands (3); 174, 130 and 112 patients, respectively. All 
patients were treated with high dose (chemo-) radiotherapy, 
but received no surgery. The C statistic was reported, Kaplan 
Meier (KM) curves were created for survival and Follow-up 
(FU) time. In addition, for all patients a linear predictor (LP) 
was computed by multiplying each variable with its 
regression coefficient and subsequently sum up the results. 
High LP-values indicate a worse prognosis according to the 
risk factors included in the model. The distributions of the 
LPs were compared graphically (Figure 1).  
Results: While the model achieved a C statistic of 0.63 in the 
development cohort (bootstrap), this decreased to 0.59, 0.56 
and 0.49, respectively, in the validation cohorts. Dataset 1 
included a more homogeneous population with a better 
prognosis according to the LP distribution, which was 
confirmed by the KM curve. Based on the LP distribution for 
dataset 2 and 3 it was expected that these cohorts had 
comparable but worse survival outcome than the 
development cohort. However, although the two-year overall 
survival was indeed similar being 44%, it was higher than that 
of the development cohort. The FU at two-years was 94% in 
the development cohort, while this was 59%, 89% and 51%, 
respectively, for the validation datasets, indicating major 
differences in either follow-up regimen or access to patient 
outcome data. 
Conclusions: A more extensive model validation reveals 
important information. To improve survival prediction for 
individual stage III NSCLC patients, more detailed information 
about patient populations and local policies, including 
specific diagnostic, treatment and follow-up procedures, is 
needed. An effort should be made to identify and collect 
these metadata electronically, applying a Big Data approach. 
Ultimately, this will enable us to develop more valid models 
for stage III NSCLC patients.  
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Purpose/Objective: To analyse the prognostic value of 
primary tumor FDG-response in serial PET/CTs during 
induction treatment with respect to overall survival. Relative 
SUV decrease is a known prognostic factor for histopathologic 
response after neoadjuvant RTCT in lung cancer. A 
confirmatory analysis of the prognostic value of relative SUV 
decrease was performed using outcome data from a 
randomized trial on definitive radiochemotherapy (RT/CT) 
compared with neoadjuvant RT/CT+surgery (trimodality). 
Materials and Methods: Pts with pathologically proven 
operable IIIA(N2) / selected IIIB NSCLC received 3 cycles 
cisplatin/paclitaxel and neoadjuvant chemoradiotherapy to 
45 Gy (1.5 Gy bid/ concurrent cisplatin/ vinorelbine). 
PET/CTs were recommended before initiation of induction 
treatment(time point t1), and before radiotherapy planning 
(9 weeks later, t2). Pts were reevaluated within an 
interdisciplinary panel during last week of RT/CT. Operable 
pts were randomized either to definitive RTCT (arm A: defRT 
to 65/71 Gy, concurrent cisplatin/vinorelbine) or surgery 
(arm B). SUVmax ratios (relSUVmax=SUVmax(t2)/SUVmax(t1)) 
were analysed as a continuous variable in proportional hazard 
analysis together with clinical pretreatment variables such as 
T and N categories, age, gender, and ECOG status, as well as 
treatment arm. 
Results: Between 1/2004 and 8/2012, 115 pts from a single 
centre were randomized in this trial. All had initial PET/CT 
investigations. From 105 patients (51 pts in arm A, 54 in arm 
B) SUVmax values from both time points (before treatment 
and before planning of the first radiotherapy series up to 45 
Gy) were available. In univariate and multivariable analysis 
of these 105 patients, relSUVmax was a significant prognostic 
factor for survival (p=0.019 and 0.015, respectively). In 
multivariable analysis, among all the above listed parameters 
relSUVmax turned out to be the strongest predictor of 
survival associated with a hazard ratio of death of 2.81 (1.23-
6.46). Treatment arm did not become significant. 5-year 
survival among patients with relSUVmax values in the upper 
quartile (>0.57) was 27% and for patients in the lowest 
quartile with relSUVmax <0.20 was 58%. Albeit the 
interaction effect between relSUVmax and treatment arm did 
not become significant, a larger hazard ratio of 3.58 (1.19-
10.76) was observed for relSUVmax in the defRT arm in 
comparison to the trimodality arm (HR=1.89 (0.62-5.72), 
n.s.). 
Conclusions: In this confirmatory study, relative SUVmax at 
the end of induction treatment turned out as a strong 
prognostic factor for survival in LAD-NSCLC especially after 
